Pages that link to "Q24561454"

The following pages link to Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides (Q24561454):

Displaying 50 items.

• Mechanisms of cellular uptake of cell-penetrating peptides (Q21296784) ‎ (← links)
• Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs (Q24569504) ‎ (← links)
• Steric antisense inhibition of AMPA receptor Q/R editing reveals tight coupling to intronic editing sites and splicing (Q24630687) ‎ (← links)
• Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients (Q24670228) ‎ (← links)
• Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy (Q24679378) ‎ (← links)
• Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications (Q24682555) ‎ (← links)
• Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials (Q26741409) ‎ (← links)
• Small RNAs: essential regulators of gene expression and defenses against environmental stresses in plants (Q26765946) ‎ (← links)
• Oligonucleotide Therapies: The Past and the Present (Q27002403) ‎ (← links)
• Antisense oligonucleotides: treating neurodegeneration at the level of RNA (Q27007056) ‎ (← links)
• The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression (Q28083838) ‎ (← links)
• Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development (Q28478166) ‎ (← links)
• Silencing disease genes in the laboratory and the clinic (Q29039090) ‎ (← links)
• RNA and disease (Q29615183) ‎ (← links)
• Oligonucleotide‐Based Knockdown Technologies: Antisense Versus RNA Interference (Q33193599) ‎ (← links)
• Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon (Q33278100) ‎ (← links)
• Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing (Q33319324) ‎ (← links)
• Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides (Q33325470) ‎ (← links)
• Future alternative therapies for β-thalassemia (Q33659678) ‎ (← links)
• Rational design of antisense oligomers to induce dystrophin exon skipping. (Q33713852) ‎ (← links)
• Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles (Q33715654) ‎ (← links)
• MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing (Q33783196) ‎ (← links)
• Optimal antisense target reducing INS intron 1 retention is adjacent to a parallel G quadruplex (Q33843189) ‎ (← links)
• Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro (Q33843195) ‎ (← links)
• Morpholino antisense oligomers: the case for an RNase H-independent structural type (Q33901587) ‎ (← links)
• Novel mechanisms for antisense-mediated regulation of gene expression (Q33916092) ‎ (← links)
• Molecular mechanisms of action of antisense drugs (Q33916100) ‎ (← links)
• 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation (Q33916133) ‎ (← links)
• Toward the therapeutic editing of mutated RNA sequences (Q33966477) ‎ (← links)
• RNA repair: a novel approach to gene therapy (Q34079549) ‎ (← links)
• Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe (Q34199543) ‎ (← links)
• RNA therapeutics: beyond RNA interference and antisense oligonucleotides (Q34248493) ‎ (← links)
• Potent and selective inhibition of A-to-I RNA editing with 2'-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides. (Q34326918) ‎ (← links)
• Sensitivity of splice sites to antisense oligonucleotides in vivo. (Q34361787) ‎ (← links)
• Anti-tumor activity of splice-switching oligonucleotides (Q34401490) ‎ (← links)
• Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse (Q34582428) ‎ (← links)
• The influence of antisense oligonucleotide length on dystrophin exon skipping. (Q34590393) ‎ (← links)
• Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome (Q34626870) ‎ (← links)
• Alternative splicing as a therapeutic target for human diseases (Q34790134) ‎ (← links)
• Screening for antisense modulation of dystrophin pre-mRNA splicing (Q34807136) ‎ (← links)
• Stress-induced endogenous siRNAs targeting regulatory intron sequences in Brachypodium. (Q35113601) ‎ (← links)
• Antisense oligonucleotide induction of progerin in human myogenic cells (Q35180565) ‎ (← links)
• Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing (Q35202462) ‎ (← links)
• Engineered Ribozymes as Molecular Tools for Site‐Specific Alteration of RNA Sequence (Q35549357) ‎ (← links)
• Antisense oligonucleotide-based therapeutics for cancer (Q35603393) ‎ (← links)
• Structural features of a 3' splice site in influenza a (Q35681726) ‎ (← links)
• Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. (Q35694248) ‎ (← links)
• Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing (Q35740521) ‎ (← links)
• Nonsense-mediated decay approaches the clinic (Q35851264) ‎ (← links)
• Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms (Q35870795) ‎ (← links)